These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 26159484)

  • 1. Dendritic hexadecapeptide as a cathepsin B degradable carrier for delivery of HSP90 inhibitor.
    Kolhatkar V; Suárez J; Kolhatkar R
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3744-7. PubMed ID: 26159484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of HSP90 Inhibitor Using Water Soluble Polymeric Conjugates with High Drug Payload.
    Suárez Del Pino JA; Kolhatkar R
    Pharm Res; 2017 Dec; 34(12):2735-2748. PubMed ID: 28913790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour eradication using synchronous thermal ablation and Hsp90 chemotherapy with protein engineered triblock biopolymer-geldanamycin conjugates.
    Chen Y; Youn P; Pysher TJ; Scaife CL; Furgeson DY
    Int J Hyperthermia; 2014 Dec; 30(8):550-64. PubMed ID: 25403416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of HSP90 inhibitor geldanamycin.
    Bae Y; Buresh RA; Williamson TP; Chen TH; Furgeson DY
    J Control Release; 2007 Sep; 122(1):16-23. PubMed ID: 17651857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition.
    Burkitt M; Magee C; O'Connor D; Campbell F; Cornford P; Greenhalf W
    Mol Carcinog; 2007 Jun; 46(6):466-75. PubMed ID: 17219417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermo-targeted drug delivery of geldanamycin to hyperthermic tumor margins with diblock elastin-based biopolymers.
    Chen Y; Youn P; Furgeson DY
    J Control Release; 2011 Oct; 155(2):175-83. PubMed ID: 21846483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
    Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
    Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin B degradable star-shaped peptidic macromolecules for delivery of 2-methoxyestradiol.
    Shankar R; Samykutty A; Riggin C; Kannan S; Wenzel U; Kolhatkar R
    Mol Pharm; 2013 Oct; 10(10):3776-88. PubMed ID: 23971990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions.
    Suzuki Y; Kondo Y; Hara S; Kimata R; Nishimura T
    Int J Urol; 2010 Mar; 17(3):281-5. PubMed ID: 20409220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.
    Borgman MP; Ray A; Kolhatkar RB; Sausville EA; Burger AM; Ghandehari H
    Pharm Res; 2009 Jun; 26(6):1407-18. PubMed ID: 19225872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
    Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
    Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles.
    Forrest ML; Zhao A; Won CY; Malick AW; Kwon GS
    J Control Release; 2006 Nov; 116(2):139-49. PubMed ID: 16926059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.
    Borgman MP; Aras O; Geyser-Stoops S; Sausville EA; Ghandehari H
    Mol Pharm; 2009; 6(6):1836-47. PubMed ID: 19743884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Maddocks K; Hertlein E; Chen TL; Wagner AJ; Ling Y; Flynn J; Phelps M; Johnson AJ; Byrd JC; Jones JA
    Leuk Lymphoma; 2016 Sep; 57(9):2212-5. PubMed ID: 26764527
    [No Abstract]   [Full Text] [Related]  

  • 15. Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations.
    Burris HA; Berman D; Murthy B; Jones S
    Cancer Chemother Pharmacol; 2011 May; 67(5):1045-54. PubMed ID: 20652703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity.
    Onodera H; Kaneko M; Takahashi Y; Uochi Y; Funahashi J; Nakashima T; Soga S; Suzuki M; Ikeda S; Yamashita Y; Rahayu ES; Kanda Y; Ichimura M
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1588-91. PubMed ID: 18243703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates.
    Kasuya Y; Lu ZR; Kopecková P; Tabibi SE; Kopecek J
    Pharm Res; 2002 Feb; 19(2):115-23. PubMed ID: 11883637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells.
    Mabjeesh NJ; Post DE; Willard MT; Kaur B; Van Meir EG; Simons JW; Zhong H
    Cancer Res; 2002 May; 62(9):2478-82. PubMed ID: 11980636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG.
    Wang S; Wang X; Du Z; Liu Y; Huang D; Zheng K; Liu K; Zhang Y; Zhong X; Wang Y
    Biochem Biophys Res Commun; 2014 Jul; 450(1):73-80. PubMed ID: 24879994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.